| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 German Primate Centre, Kellnerweg 4, D-37077 Goettingen, Germany
2 Institute of Medical Chemistry and Biochemistry and Ludwig-Boltzmann-Institute for AIDS Research, University of Innsbruck, Innsbruck, Austria
3 Health Canada, Bureau for HIV/AIDS, Laboratory Centre for Disease Control, Ottawa, Canada
Convincing data on experimental vaccines against AIDS have been obtained in the simian immuno-deficiency virus (SIV) macaque model by preinfection with a virus attenuated by a nef deletion. To investigate the efficacy of a nef deletion mutant of SIVmac32H called pC8 as a live-attenuated vaccine after shorter preinfection periods and to learn more about the nature of the immune protection induced, eight rhesus monkeys were infected intravenously with the pC8 virus. All monkeys became persistently infected, exhibiting low cell-associated viral loads, but strong cellular and, in terms of binding antibodies, strong humoral antiviral responses. Two of eight pC8-infected monkeys developed an immuno-deficiency and were not challenged. Sequence analysis of their nef revealed complete replenishment of the deletion. The other six monkeys, two preinfected for 42 weeks and four for 22 weeks, were challenged with pathogenic spleen-derived SIV. Complete protection was achieved in four vaccinees. Virus was consistently detected in two vaccinees from the 22-week-group challenge, however, they remained clinically healthy over a prolonged period. Protection from challenge virus infection or a delayed disease development seemed to be associated with a sustained SIV-specific T helper cell response after challenge. Thus, a sterilizing immunity against superinfection with pathogenic SIV can be induced even after a relatively short waiting period of 22 weeks. Nevertheless, such a vaccine raises severe safety concerns because of its potential to revert to virulence.
Received 29 May 1996;
accepted 7 August 1996.
This article has been cited by other articles:
|
|
 |
|
  R. Stebbings, N. Berry, H. Waldmann, P. Bird, G. Hale, J. Stott, D. North, R. Hull, J. Hall, J. Lines, et al. CD8+ Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus J. Virol., October 1, 2005; 79(19): 12264 - 12272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tenner-Racz, C. S. Hennig, K. Uberla, H. Stoiber, R. Ignatius, J. Heeney, R. M. Steinman, and P. Racz Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus PNAS, March 2, 2004; 101(9): 3017 - 3022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abel, L. Compton, T. Rourke, D. Montefiori, D. Lu, K. Rothaeusler, L. Fritts, K. Bost, and C. J. Miller Simian-Human Immunodeficiency Virus SHIV89.6-Induced Protection against Intravaginal Challenge with Pathogenic SIVmac239 Is Independent of the Route of Immunization and Is Associated with a Combination of Cytotoxic T-Lymphocyte and Alpha Interferon Responses J. Virol., March 1, 2003; 77(5): 3099 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jost, M.-C. Bernard, L. Kaiser, S. Yerly, B. Hirschel, A. Samri, B. Autran, L.-E. Goh, and L. Perrin A Patient with HIV-1 Superinfection N. Engl. J. Med., September 5, 2002; 347(10): 731 - 736. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Borkow and Z. Bentwich Host Background Immunity and Human Immunodeficiency Virus Protective Vaccines, a Major Consideration for Vaccine Efficacy in Africa and in Developing Countries Clin. Vaccine Immunol., May 1, 2002; 9(3): 505 - 507. [Full Text] [PDF]
|
|
|
|
|
|
C. Stahl-Hennig, R. M. Steinman, P. Ten Haaft, K. Uberla, N. Stolte, S. Saeland, K. Tenner-Racz, and P. Racz The Simian Immunodeficiency Virus {Delta}nef Vaccine, after Application to the Tonsils of Rhesus Macaques, Replicates Primarily within CD4+ T Cells and Elicits a Local Perforin-Positive CD8+ T-Cell Response J. Virol., January 15, 2002; 76(2): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Khatissian, V. Monceaux, M.-C. Cumont, M.-P. Kieny, A.-M. Aubertin, and B. Hurtrel Persistence of Pathogenic Challenge Virus in Macaques Protected by Simian Immunodeficiency Virus SIVmac{Delta}nef J. Virol., February 1, 2001; 75(3): 1507 - 1515. [Abstract] [Full Text]
|
|
|
|
|
|
K. Verhoef, G. Marzio, W. Hillen, H. Bujard, and B. Berkhout Strict Control of Human Immunodeficiency Virus Type 1 Replication by a Genetic Switch: Tet for Tat J. Virol., January 15, 2001; 75(2): 979 - 987. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Gorelick, R. E. Benveniste, J. D. Lifson, J. L. Yovandich, W. R. Morton, L. Kuller, B. M. Flynn, B. A. Fisher, J. L. Rossio, M. Piatak Jr., et al. Protection of Macaca nemestrina from Disease following Pathogenic Simian Immunodeficiency Virus (SIV) Challenge: Utilization of SIV Nucleocapsid Mutant DNA Vaccines with and without an SIV Protein Boost J. Virol., December 15, 2000; 74(24): 11935 - 11949. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. J. Metzner, X. Jin, F. V. Lee, A. Gettie, D. E. Bauer, M. Di Mascio, A. S. Perelson, P. A. Marx, D. D. Ho, L. G. Kostrikis, et al. Effects of In Vivo CD8+ T Cell Depletion on Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine J. Exp. Med., June 6, 1999; 191(11): 1921 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Sodora, K. E. Sheridan, P. A. Marx, and R. I. Connor Immunization with a Live, Attenuated Simian Immunodeficiency Virus Vaccine Leads to Restriction of Viral Diversity in Rhesus Macaques Not Protected from Pathogenic Challenge J. Virol., May 1, 1999; 73(5): 4443 - 4446. [Abstract] [Full Text]
|
|
|
|
|
|
S. Carl, A. J. Iafrate, J. Skowronski, C. Stahl-Hennig, and F. Kirchhoff Effect of the Attenuating Deletion and of Sequence Alterations Evolving In Vivo on Simian Immunodeficiency Virus C8-Nef Function J. Virol., April 1, 1999; 73(4): 2790 - 2797. [Abstract] [Full Text]
|
|
|
|
 |
|
 P Caufour, R Le Grand, A Cheret, O Neildez, F Theodoro, B Boson, B Vaslin, and D Dormont Secretion of beta-chemokines by bronchoalveolar lavage cells during primary infection of macaques inoculated with attenuated nef-deleted or pathogenic simian immunodeficiency virus strain mac251 J. Gen. Virol., March 1, 1999; 80(3): 767 - 776. [Abstract]
|
|
|
|
|
|
B. Berkhout, K. Verhoef, J. L. B. van Wamel, and N. K. T. Back Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains J. Virol., February 1, 1999; 73(2): 1138 - 1145. [Abstract] [Full Text]
|
|
|
|
|
|
M. G. Lewis, J. Yalley-Ogunro, J. J. Greenhouse, T. P. Brennan, J. B. Jiang, T. C. VanCott, Y. Lu, G. A. Eddy, and D. L. Birx Limited Protection from a Pathogenic Chimeric Simian-Human Immunodeficiency Virus Challenge following Immunization with Attenuated Simian Immunodeficiency Virus J. Virol., February 1, 1999; 73(2): 1262 - 1270. [Abstract] [Full Text]
|
|
|
|
|
|
S. V. Joag, Z. Q. Liu, E. B. Stephens, M. S. Smith, A. Kumar, Z. Li, C. Wang, D. Sheffer, F. Jia, L. Foresman, et al. Oral Immunization of Macaques with Attenuated Vaccine Virus Induces Protection against Vaginally Transmitted AIDS J. Virol., November 1, 1998; 72(11): 9069 - 9078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Connor, D. C. Montefiori, J. M. Binley, J. P. Moore, S. Bonhoeffer, A. Gettie, E. A. Fenamore, K. E. Sheridan, D. D. Ho, P. J. Dailey, et al. Temporal Analyses of Virus Replication, Immune Responses, and Efficacy in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine J. Virol., September 1, 1998; 72(9): 7501 - 7509. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
